Insulin‑Aspart‑Szjj Suppliers & Bulk Manufacturers
Available Forms: SQ Injection
Available Strengths: 100 units/mL
Reference Brands: NovoLog; Merilog is biosimilar to NovoLog.
Category:
Biosimilars
Merilog, a biosimilar to NovoLog (insulin aspart), mimics natural insulin by stimulating glucose uptake in tissues, reducing blood sugar levels. It provides rapid, consistent blood glucose control, supports flexible dosing, and offers similar efficacy, safety, and benefits as the original, supporting effective diabetes management when used under medical supervision.
Insulin‑aspart‑szjj is available in SQ Injection
and strengths such as 100 units/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Insulin‑aspart‑szjj is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Insulin‑aspart‑szjj can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Merilog is regulated as a biosimilar to NovoLog (insulin aspart) in both the EU and US. In the US, FDA approval involves extensive comparability, safety, and efficacy data in accordance with GMP standards. In the EU, CE marking certifies conformity with MDR standards for biosimilarity, validated through dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality. These biosimilars undergo validation, stability testing, and audits, supported by comprehensive documentation including clinical data, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to affordable, high-quality insulin biosimilars supporting optimal diabetes management worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing